During the corresponding time, Prime Medicine Inc recorded a revenue increase by 3.5 % year on year, sequentially revenue grew by 34.81 %. While revenue at the Prime Medicine Inc 's corporate clients
Prime Medicine Inc's Comment on Sales, Marketing and Customers
The company has a licensing agreement with Broad Institute for licensed products targeting specific patient populations. The agreement requires annual license maintenance fees and includes clinical and regulatory milestone payments of up to $20 million per licensed product, as well as sales-based milestone payments of up to $54 million per licensed product. Royalties on net sales are also payable, with rates varying based on whether the products are licensed or enabled and the patient populations treated. Broad Institute is entitled to a percentage of sublicense consideration. The agreement assigns responsibilities for patent prosecution, maintenance, and enforcement of licensed patent rights within the Prime Broad Field. The term of the agreement extends until the expiration of the relevant patent claims or royalty periods, with provisions allowing either party to terminate under specified conditions.
Prime Medicine, a biotechnology company specializing in gene editing technologies, has announced a strategic research collaboration and licensing agreement with Bristol Myers Squibb (BMS), a leading biopharmaceutical firm. This partnership aims to develop and commercialize a range of innovative T-cell therapies that utilize Prime Medicine s cutting-edge gene editing capabilities.The collaboration centers on Prime Medicine s unique approach to gene editing, specifically its precise and multiplex editing technology. This advanced technique allows for the targeted alteration of multiple genes simultaneously, opening new pathways for the development of therapies aimed at treating various diseases, including canc...
Chronic Granulomatous Disease (CGD) is a rare genetic disorder that affects the innate immune system, leaving patients more susceptible to recurrent infections and inflammatory complications. The pioneering work of Prime Medicine presents a potential breakthrough in the treatment of CGD, with preclinical data showcasing the impressive efficacy, reproducibility, and durability of their candidate drug, PM359, in correcting the causative mutation responsible for this debilitating condition.Key Findings:In a comprehensive preclinical study, Prime Medicine s research team evaluated the effectiveness of PM359 in correcting the mutated gene responsible for CGD. Using innovative genome-editing technology, PM359 demo...
Prime Medicine Inc’s Comment on Sales, Marketing and Customers
The company has a licensing agreement with Broad Institute for licensed products targeting specific patient populations. The agreement requires annual license maintenance fees and includes clinical and regulatory milestone payments of up to $20 million per licensed product, as well as sales-based milestone payments of up to $54 million per licensed product. Royalties on net sales are also payable, with rates varying based on whether the products are licensed or enabled and the patient populations treated. Broad Institute is entitled to a percentage of sublicense consideration. The agreement assigns responsibilities for patent prosecution, maintenance, and enforcement of licensed patent rights within the Prime Broad Field. The term of the agreement extends until the expiration of the relevant patent claims or royalty periods, with provisions allowing either party to terminate under specified conditions.
Sources:
Prime Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Prime Medicine Inc’s corporate clients.
For your research, we’ve provided 9 tables on Prime Medicine Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
